TP53 aberrations also have paramount prognostic value in treated patients with CLL since, generally, they confer a worse prognosis with all available treatments, including agents targeting B cell receptor (BcR) signaling and BCL2, at least in the relapsed/refractory setting [30–33]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.